BRIEF-Protara Therapeutics Q2 EPS USD -0.36

Moderna has recently received consecutive rating upgrades from five institutions due to positive clinical data from its melanoma mRNA cancer vaccine. Argus analyst Hellweg upgraded the company's rating from "hold" to "buy," noting that the stock price is currently trading at over a 70% discount from its historical peak and believing that "the tide is turning." He emphasized that the stock price increase driven by existing data is just the beginning, and that continued positive confirmatory data will provide stronger upward momentum.